This year, Alfasigma will be Sponsor of the Vein Week, organized by v-WIN Foundation (Scientific Society in Phlebology). The initiative will take place from April, 5th to 11th and on the occasion, a Geomap Calendar software was developed, showing, within an interactive map, vascular events uploaded to the platform by the organizers themselves, upon approval of v-WIN Foundation.
Alfasigma acquires Lumeblue™ (Methylene Blue MMX) rights for EU distribution, consolidating its Gastro-Intestinal portfolio
Cosmo Pharmaceuticals will receive a €4m upfront payment Alfasigma plus double digit royalties.
Lumeblue™ was ecently approved by EMA for the detection of lesions during colonoscopy.
Alfasigma will distribute Lumeblue™ in EU, Switzerland, UK, European Economic Area countries, Russia and Mexico.
The new corporate Alfasigma Russia website is online (https://ru.alfasigma.com/). This new website meets most modern technical requirements, has a striking design and a very user friendly interface.
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis).
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies and ventricular arrhythmia are the main pathologies in which we offer solutions.
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles.
Nutraceuticals & Medical foods
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue.